CIBC is bullish on ITMN. They cover the company with Stock Rating: Sector Outperformer.
This is from a March 22, 2007 report:
Given the solid Shionogi data, we believe there will be additional upside in ITMN today. Based on our continued confidence in pirfenidone's probability of success, and the likelihood of positive antiviral data for ITMN-191 in HCV in 2H07, we believe ITMN shares remain attractive.
Important Disclosure Footnotes for InterMune, Inc. (ITMN)
1 CIBC World Markets Corp. makes a market in the securities of InterMune, Inc.
